| Literature DB >> 32308445 |
Mojtaba Moosavian1,2, Paria Baratian Dehkordi2, Mohammad Hashemzadeh1,2.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most pathogens associated with health care. Molecular typing methods are vital for outbreak investigations of MRSA. The aim of this study was characterization of SCCmec, spa types and multidrug resistant of methicillin-resistant Staphylococcus aureus isolates in Ahvaz, Iran.Entities:
Keywords: Antibiotic resistance; HRM; high-resolution melting; multidrug resistant Staphylococcus aureus; spa-typing
Year: 2020 PMID: 32308445 PMCID: PMC7154036 DOI: 10.2147/IDR.S244896
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Characteristics of MRSA isolates from Patients Seen at the University Hospitals of Ahvaz, Iran
| MSRA | Age | Gender | Hospital | Source | Ward | HRM-Based spa-Typing | PCR-Based spa-Typing | ARPs | MDR | XDR | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 29 | F | Razi | Blood | ICU | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
| 2 | 33 | M | Golestan | Urine | Nephrology | t037 | t037 | CD,E,T,FOX | + | − | II |
| 3 | 39 | F | Golestan | Blood | Surgery | t030 | t030 | CIP,CD,E,GN,RP,T,FOX | + | − | II |
| 4 | 54 | F | Razi | Urine | ICU | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | IV |
| 5 | 63 | F | Golestan | Urine | Pediatric | t030 | t030 | CIP,CD,RP,T,FOX | + | − | III |
| 6 | 51 | F | Golestan | Blood | Pediatrics ICU | t030 | t030 | CIP,CD,E,GN,RP,T,FOX | + | − | II |
| 7 | 45 | M | Razi | Blood | Women | t037 | t037 | CD,E,RP,T,FOX | + | − | NT |
| 8 | 64 | F | Razi | Abscesses | Surgery | t037 | t037 | SXT,CD,RP,T,FOX | + | − | II |
| 9 | 54 | F | Razi | Urine | Emergency | t363 | t363 | CIP,CD,T,FOX | + | − | II |
| 10 | 42 | M | Taleghani | Urine | Emergency | t037 | t037 | CIP,CD,E,RP,T,FOX | + | − | I |
| 11 | 47 | F | Golestan | Abscesses | Pediatrics ICU | t030 | t030 | CIP,CD,E,RP,T,FOX | + | − | NT |
| 12 | 43 | F | Razi | Urine | Women | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
| 13 | 52 | F | Razi | Urine | Emergency | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
| 14 | 28 | M | Razi | Blood | ICU | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
| 15 | 32 | F | Golestan | Abscesses | ICU | t030 | t030 | CIP,CD,E,T,FOX | + | − | I |
| 16 | 36 | F | Taleghani | Wound | ICU | t030 | t030 | CIP,CD,T,FOX | + | − | II |
| 17 | 21 | F | Razi | Blood | ICU | t037 | t037 | CIP,CD,GN,RP,T,FOX | + | − | II |
| 18 | 51 | F | Golestan | Synovial fluid | Surgery | t030 | t030 | CIP,CD,GN,RP,FOX | + | − | II |
| 19 | 53 | M | Taleghani | Blood | ICU | t037 | t037 | SXT,C,CD,GN,RP,T,FOX | + | − | IV |
| 20 | 36 | F | Razi | Wound | ICU | t037 | t037 | CIP,CD,GN,RP,T,FOX | + | − | IV |
| 21 | 37 | F | Golestan | Blood | ICU | t030 | t030 | SXT,C,RP,FOX | + | − | II |
| 22 | 51 | F | Razi | Wound | Women | t030 | t030 | CD,E,GN,RP,FOX | + | − | I |
| 23 | 62 | M | Razi | Blood | Surgery | t275 | t275 | CD,E,FOX | + | − | II |
| 24 | 41 | M | Golestan | Wound | Pediatrics ICU | t037 | t037 | C,CD,FOX | + | − | III |
| 25 | 48 | M | Razi | Blood | ICU | t030 | t030 | SXT,C,CD,E,GN,RP,T,FOX | + | − | III |
| 26 | 58 | M | Razi | Wound | Surgery | t034 | t034 | CD,E,FOX | + | − | III |
| 27 | 54 | F | Razi | Wound | ICU | t037 | t037 | CD,E,GN,FOX | + | − | III |
| 28 | 27 | M | Golestan | Blood | Pediatric | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
| 29 | 41 | M | Razi | Blood | ICU | t030 | t030 | CIP,CD,E,GN,FOX | + | − | III |
| 30 | 52 | F | Golestan | Blood | Surgery | t037 | t037 | C,E,GN,FOX | + | − | II |
| 31 | 36 | M | Razi | Synovial fluid | Orthopedic | t030 | t030 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
| 32 | 63 | F | Razi | Wound | ICU | t459 | t459 | CIP,GN,FOX | + | − | III |
| 33 | 30 | M | Golestan | Wound | Pediatric | t037 | t037 | SXT,C,CD,E,GN,RP,T,FOX | + | − | III |
| 34 | 63 | M | Razi | Urine | Surgery | t030 | t030 | CIP,E,GN,FOX | + | − | III |
| 35 | 61 | F | Golestan | Wound | ICU | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | II |
| 36 | 39 | M | Razi | Wound | Surgery | t363 | t363 | CIP,CD,E,GN,FOX | + | − | IV |
| 37 | 47 | F | Golestan | Wound | ICU | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | II |
| 38 | 46 | M | Razi | Wound | Surgery | t304 | t304 | CIP,FOX | + | − | II |
| 39 | 52 | F | Razi | Wound | Women | t030 | t030 | CIP,E,GN,T,FOX | + | − | III |
| 40 | 35 | M | Razi | Wound | ICU | t030 | t030 | E,GN,T,CIP,FOX | + | − | III |
| 41 | 42 | M | Razi | Synovial fluid | Orthopedic | t030 | t030 | SXT,C,CD,E,GN,T,FOX | + | − | III |
| 42 | 61 | F | Golestan | Urine | Nephrology | t037 | t037 | CIP,CD,E,GN,RP,T,FOX | + | − | III |
| 43 | 37 | M | Razi | Synovial fluid | ICU | t459 | t459 | CD,E,FOX | + | − | II |
| 44 | 33 | M | Razi | Urine | Emergency | t189 | t189 | CD,E,GN,RP,T,FOX | + | − | IV |
| 45 | 46 | F | Razi | Urine | Emergency | t030 | t030 | SXT,CIP,CD,E,GN,FOX | + | − | III |
| 46 | 28 | M | Razi | Abscesses | Surgery | t044 | t044 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
| 47 | 53 | F | Golestan | Urine | ICU | t037 | t037 | CIP,CD,E,GN,FOX | + | − | II |
| 48 | 27 | F | Golestan | Urine | ICU | t037 | t037 | SXT,CIP,CD,E,GN,RP,FOX | + | − | II |
| 49 | 48 | F | Razi | Urine | Emergency | t030 | t030 | CIP,CD,E,GN,FOX | + | − | IV |
| 50 | 62 | F | Golestan | Urine | Emergency | t037 | t037 | SXT,C,CIP,CD,E,GN,RP,T,FOX | − | + | III |
Total Distribution of MRSA Among Different Clinical Specimens of Three Major Hospitals
| Hospital | ||||||
|---|---|---|---|---|---|---|
| Clinical Specimens | Razi Hospital | Golestan Hospital | Taleghani Hospital | |||
| MRSA (29) | MSSA(49) | MRSA (18) | MSSA (20) | MRSA (3) | MSSA (27) | |
| Blood | 7 | 18 | 5 | 10 | 1 | 14 |
| Wound | 9 | 12 | 4 | 5 | 1 | 9 |
| Synovial fluid | 3 | 3 | 1 | 1 | – | 1 |
| Urine | 8 | 11 | 6 | 4 | 1 | 3 |
| Abscesses | 2 | 5 | 2 | – | – | – |
Results of Antimicrobial Resistance Tests by Disk Diffusion Method for MRSA
| Antimicrobial Category | Antimicrobial Agent | Negative | Positive | Pvalue |
|---|---|---|---|---|
| Oxazolidinones | Linezolid | 50(100%) | – | |
| Folat pathway inhibitors | Trimethoprim-sulphamethoxazole | 31(62%) | 19(38%) | 0.090 |
| Phenicols | Chloramphenicol | 32(64%) | 18(36%) | 0.048* |
| Fluoroquinolones | Ciprofloxacin | 16(32%) | 34(68%) | 0.011* |
| Lincosamides | Clindamycin | 7(14%) | 43(86%) | <0.0001* |
| Macrolides | Erythromycin | 12(24%) | 38(76%) | <0.0001* |
| Aminoglycosides | Gentamycin | 15(31%) | 35(69%) | 0.005* |
| Ansamycins | Rifampin | 21(42%) | 29(58%) | 0.258 |
| Tetracyclines | Tetracycline | 18(36%) | 32(64%) | 0.048* |
| Glycopeptides | Vancomycin | 50(100%) | – | |
| Penicillinase-stable penicillins | Cefoxitin | – | 50(100%) |
Note: *Denotes statistically significant difference between resistance and susceptible MRSA isolated.
Multidrug Resistance Patterns Among MRSA Isolates
| Number of Resistant Antibiotics | Antibiotics | Number of Species |
|---|---|---|
| 9 | SXT,C,CIP,CD,E,GN,RP,T,FOX | 11 |
| 8 | SXT,C,CD,E,GN,RP,T,FOX | 2 |
| 7 | CIP,CD,E,GN,RP,T,FOX | 3 |
| SXT,C,CD,GN,RP,T,FOX | 1 | |
| SXT,C,CD,E,GN,T,FOX | 1 | |
| SXT,CIP,CD,E,GN,RP,FOX | 1 | |
| 6 | CIP,CD,RP,T,CIP,FOX | 1 |
| CIP,CD,E,RP,T,FOX | 2 | |
| CIP,CD,GN,RP,T,FOX | 2 | |
| CD,E,GN,RP,T,FOX | 1 | |
| SXT,CIP,CD,E,GN,FOX | 1 | |
| 5 | CD,E,RP,T,FOX | 1 |
| SXT,CD,RP,T,FOX | 1 | |
| CIP,CD,E,T,FOX | 1 | |
| CIP,CD,GN,RP,FOX | 1 | |
| CD,E,GN,RP,FOX | 1 | |
| CIP,CD,E,GN,FOX | 4 | |
| CIP,E,GN,T,FOX | 2 | |
| 4 | CD,E,T,FOX | 2 |
| CIP,CD,T,FOX | 2 | |
| SXT,C,RP,FOX | 1 | |
| C,E,GN,FOX | 1 | |
| CIP,E,GN,FOX | 1 | |
| 3 | CD,E,FOX | 3 |
| C,CD,FOX | 1 | |
| CIP,GN,FOX | 1 | |
| 2 | CIP,FOX | 1 |
Figure 1Distribution of antibiotic resistance in MRSA with spa types.
HRM and Spa Sequence Types of the 50 MRSA Isolates, and the Frequencies in the Hospital of Origin
| HRM | Tm | Spa-Type | Repeat of Spa Type | Size, bp | CG% | Number of Isolates |
|---|---|---|---|---|---|---|
| 1 | 82.30 | T030 | 15-12-16-02-24-24 | 144 | 45 | 18 |
| 2 | 82.50 | T037 | 15-12-16-02-25-17-24 | 168 | 45.2 | 22 |
| 3 | 82.55 | T363 | 15-16-02-25-17-24 | 144 | 45.8 | 2 |
| 4 | 82.15 | T459 | 15-12-16-02-24 | 120 | 44 | 2 |
| 5 | 82.23 | T189 | 07-23-12-12-21-17-34 | 168 | 43 | 1 |
| 6 | 82.00 | T304 | 11-10-21-17-34-24-34-22-25 | 216 | 43.5 | 1 |
| 7 | 81.80 | T034 | 11-17-34-24-34-22-25 | 168 | 44 | 1 |
| 8 | 82.75 | T275 | 15-12-16-02-25-17-24-24 | 192 | 44 | 1 |
| 9 | 81.38 | T325 | 7-12-21-17-34-13-34-34-33-34 | 240 | 40.4 | 1 |
| 10 | 81.60 | T044 | 7-23-12-34-34-33-34 | 168 | 41.7 | 1 |
Abbreviations: HRM, high-resolution melting; Tm, melting temperature.
Figure 2Comparison of different spa polymorphic region X HRM curves obtained from MRSA isolates. (A) Negative derivative of fluorescence over temperature (df/dt) plots displaying 10 HRM profiles. (B) Normalization data curve shows the decreasing fluorescence vs increasing temperature. (C) Difference graph demonstrating the accurate reproduction of eight spa HRM profiles in a run experiment. Isolates with difference plots that fall within the ±0.2 relative fluorescence unit (RFU) cutoffs were considered as the “same” type, while the isolates that lie outside of the ±0.2 RFU cutoffs were denoted as “different”.